ClinicalTrials.gg
CompletedNCT03723772Updated Mar 11, 2025

A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week

A Phase 1 interventional study of Insulin icodec and IGlar U100 in Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S — 2 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Novo Nordisk A/S.

Enrollment
68th of 149
66 · median 62
Started
2018
with 7 others
Phase 1
74 of 226
1 open now
Registered
201st of 226
by date

Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 68th largest by enrollment of the 149 interventional ones that give a count, is one of 8 that started in 2018, is one of 74 in phase 1, and was the 201st registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study compares the new long-acting insulin 287 with the marketed insulin glargine for use in type 1 diabetes. The study will test how insulin is taken up in your blood, how long it stays there and how the blood sugar is lowered. The participant will get both of the insulins in a random order. Insulin 287 is a new medicine while insulin glargine is already approved for the treatment of diabetes and can be prescribed by a doctor. The participant will get 8 weekly doses of insulin 287 and 14 daily doses of insulin glargine. There will also be a run-in period of 2 days to 4 weeks with daily doses of insulin glargine before you start the insulin 287 period. All doses will be injected under the skin. The study will last for about 16 to 24 weeks. The participant will have 27 visits with the study doctor.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18-64 years (both inclusive) at the time of signing
  • Diagnosed with type 1 diabetes mellitus greater than or equal to 1 year prior to the day of screening
  • Current daily basal insulin treatment greater than or equal to 0.2 U/kg/day
  • between 18.5 and 29.0 kg/m\^2 (both inclusive)
  • less than or equal to 9.0%

Exclusion criteria

Exclusion Criteria:

  • History or presence of any respiratory, metabolic, renal, hepatic, gastrointestinal or endocrinological conditions. Subjects with complications associated to diabetes can be included only if they are judged to be mild by the investigator. Subjects with other comorbidities (e.g. dyslipidaemia, hypertension and hypothyroidism) can be included if they have a stable treatment and are in adequate control according to the judgement of the investigator- Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate methods (adequate contraceptive measures as required by local regulation or practice)
  • Known or suspected to trial products or related products
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Insulin 287 followed by insulin glargine U100

    Run-in period (2 days to 4 weeks): The basal insulin glargine dose for each subject will be established and optimised. After run-in, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic sampling where subjects are treated with once daily (OD) insulin glargine. After insulin 287 treatment, participants will receive insulin glargine U100 OD for 2 weeks.

    Drug: Insulin icodec · Drug: IGlar U100

  • Experimental
    Insulin glargine U100 followed by insulin 287

    Run-in period (2 days to 4 weeks): The basal insulin glargine dose for each subject will be established and optimised. After run-in, participants will receive insulin glargine U100 OD for 2 weeks followed by 1-14 days (at least 1 day is mandatory) of continued insulin glargine treatment. After insulin glargine treatment, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic sampling.

    Drug: Insulin icodec · Drug: IGlar U100

Interventions

  • Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks

    Also known as: Insulin 287

  • DrugIGlar U100

    Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.

06

What researchers measure

Primary outcomes

  1. AUCI287,τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state

    Measured in pmol\*h/L

    Time frame: From 0 to 168 hours after trial product administration (Day 50)

Secondary outcomes

  1. AUCGIR,16-52h,SS (for insulin 287) - Area under the glucose infusion rate-time curve at steady state

    Measured in mg/kg

    Time frame: From 16 to 52 hours after trial product administration (Day 50)

  2. AUCGIR,138-168h,SS (for insulin 287) - Area under the glucose infusion rate-time curve at steady state

    Measured in mg/kg

    Time frame: From 138 to 168 hours after trial product administration (Day 50)

  3. GIRmax,16-52h, SS (for insulin 287) - Maximum observed glucose infusion rate at steady state

    Measured in mg/(kg\*min)

    Time frame: From 16 to 52 hours after trial product administration (Day 50)

  4. GIRmax,138-168h, SS (for insulin 287) - Maximum observed glucose infusion rate at steady state

    Measured in mg/(kg\*min)

    Time frame: From 138 to 168 hours after trial product administration (Day 50)

  5. AUCGIR,0-24h,SS (for insulin glargine) - Area under the glucose infusion rate-time curve at steady state

    Measured in mg/kg

    Time frame: From 0 to 24 hours after trial product administration (Day 14)

  6. GIRmax,0-24h, SS (for insulin glargine) - Maximum observed glucose infusion rate at steady state

    Measured in mg/(kg\*min)

    Time frame: From 0 to 24 hours after trial product administration (Day 14)

  7. AUCI287,0-168h,FD (from insulin 287) - Area under the serum insulin 287 concentration-time curve after the first dose

    Measured in pmol\*h/L

    Time frame: From 0 to 168 hours after trial product administration (Day 1)

  8. Cmax,I287,FD (for insulin 287) - Maximum observed serum insulin 287 concentration after the first dose

    Measured in pmol/L

    Time frame: From 0 to 168 hours after trial product administration (Day 1)

  9. tmax,I287,FD (for insulin 287) - Time to maximum observed serum insulin 287 concentration after the first dose

    Measured in hours

    Time frame: From 0 to 168 hours after trial product administration (Day 1)

  10. Cmax,I287,SS (for insulin 287) - Maximum observed serum insulin 287 concentration after the last dose

    Measured in pmol/L

    Time frame: From 0 to 168 hours after trial product administration (Day 50)

  11. tmax,I287,SS (for insulin 287) - Time to maximum observed serum insulin 287 concentration after the last dose

    Measured in hours

    Time frame: From 0 to 168 hours after trial product administration (Day 50)

  12. t½,I287,SS (for insulin 287) - Terminal half-life for insulin 287 at steady state

    Measured in hours

    Time frame: Terminal part of the serum insulin 287 concentration-time curve where the curve is well approximated by a straight line on logarithmic scale after last trial product administration (Day 50)

  13. CI287,trough (for insulin 287) - Serum insulin 287 trough concentration

    Measured in pmol/L

    Time frame: Measured at the end of each dosing interval 168 hours after trial product administration (Day 8, 15, 22, 29, 36, 43, 50 and 57)

  14. AUCIGlar,τ,SS (for insulin glargine) - Area under the serum insulin glargine concentration-time curve during one dosing interval at steady state

    Measured in pmol\*h/L

    Time frame: From 0 to 24 hours after trial product administration (Day 14)

  15. Cmax,IGlar,SS (for insulin glargine) - Maximum observed serum insulin glargine concentration at steady state

    Measured in pmol/L

    Time frame: From 0 to 24 hours after trial product administration (Day 14)

  16. tmax,IGlar,SS (for insulin glargine) - Time to maximum observed serum insulin glargine concentration at steady state

    Measured in hours

    Time frame: From 0 to 24 hours after trial product administration (Day 14)

  17. CIGlar,trough (for insulin glargine) - Serum insulin glargine trough concentration

    Measured in pmol/L

    Time frame: Measured at the end of each dosing interval 24 hours after trial product administration (Day 4, 7, 14 and 15)

  18. Number of adverse events (AEs)

    Number of events

    Time frame: From first trial product administration (Day 1) to end of last dosing interval (Day 57 for insulin 287, day 15 for IGlar)

  19. Number of hypoglycaemic episodes

    Number of episodes

    Time frame: From first trial product administration (Day 1) to end of last dosing interval (Day 57 for insulin 287, day 15 for IGlar)

  20. Change in anti-insulin 287 antibody level

    Measured in % B/T (percentage of bound tracer measured after precipitation to total tracer)

    Time frame: From first insulin 287 administration (Day 1) to Follow-up visit (visit 25, day 106)

  21. Change in anti-insulin 287 antibody titres

    Number of dilutions

    Time frame: From first insulin 287 administration (Day 1) to Follow-up visit (visit 25, day 106)

  22. Positive cross-reactive anti-human insulin antibodies

    Number of patients with/without positive cross-reactive anti-human insulin antibodies

    Time frame: At the follow-up visit (Visit 25, day 106)

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, 41460, Germany
08

References and documents

Publications

  • Hovelmann U, Engberg S, Heise T, Kristensen NR, Norgreen L, Zijlstra E, Ribel-Madsen R. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes. Diabetes Obes Metab. 2024 May;26(5):1941-1949. doi: 10.1111/dom.15510. Epub 2024 Feb 20. PubMed 38379002 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jun 2020, 18 months.

Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 18 months is above that.

Counting every sponsor, half of 152 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2018
First posted
Oct 30, 2018
StartActual
Nov 29, 2018
Primary completionActual
Jun 26, 2020
CompletionActual
Jun 26, 2020
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03723772
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 30, 2018
Start date
Nov 29, 2018
Primary completion
Jun 26, 2020
Completion
Jun 26, 2020
Last update
Mar 11, 2025

Study contacts

Clinical Reporting Anchor and Disclosure (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin icodec

Start the discussion